Once-weekly injections of Roche’s CT-388 at 24 mg yielded 22.5% placebo-adjusted weight loss in a Phase II trial after 48 weeks, with 95.7% of participants losing ≥5% body weight and 26.1% losing ≥30%. Roche plans to initiate two Phase III trials (Enith1 and Enith2) this quarter.